导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 8.42% | 923/4773 |
| 近一周 | -0.71% | 1765/5467 |
| 近一月 | -6.13% | 2893/5421 |
| 近一季 | -5.30% | 1771/5238 |
| 近半年 | 1.80% | 1238/4931 |
| 近一年 | 13.40% | 812/4400 |
| 近两年 | 68.30% | 1038/2954 |
| 近三年 | 31.02% | 1033/2253 |
| 成立以来 | 18.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.52% 908/4961 |
15.27% 1688/5312 |
- - |
- - |
| 2025 | 29.29% 1413/4813 |
2.48% 1359/3635 |
2.37% 1613/4076 |
19.18% 2175/4524 |
3.40% 681/4813 |
| 2024 | -1.39% 2157/3463 |
-2.93% 1453/2808 |
-5.68% 1777/3014 |
10.73% 2600/3129 |
-2.74% 2168/3463 |
| 2023 | -7.30% 906/2656 |
8.24% 477/2280 |
-5.88% 1552/2385 |
-4.33% 1114/2515 |
-4.88% 1201/2655 |
| 2022 | -19.20% 817/2207 |
-13.77% 831/1919 |
2.85% 1246/2016 |
-12.98% 813/2113 |
4.69% 522/2208 |
| 2021 | 15.09% 312/1822 |
-1.61% 523/1255 |
9.01% 592/1330 |
4.91% 311/1466 |
2.29% 632/1822 |
| 2020 | 35.01% 426/1250 |
-0.57% 189/1028 |
18.12% 354/1067 |
9.88% 606/1164 |
4.63% 834/1184 |
| 2019 | 26.22% 579/1092 |
30.55% 241/739 |
-8.17% 581/788 |
-2.38% 698/850 |
7.85% 388/918 |
| 2018 | -31.86% 510/834 |
- - |
-13.03% 427/631 |
-6.97% 423/660 |
-13.76% 554/682 |
| 2017 | -1.21% 494/714 |
- - |
- - |
- - |
- - |
| 2016 | -15.04% 347/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 诺安中证500指数增强A VS. 长安沪深300非周期A(740101) |